Quick Answer
Lineage Cell Therapeutics, Inc. reported Net Income Loss of -$63.53 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -241.4% in Net Income Loss from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Lineage Cell Therapeutics, Inc.'s Net Income Loss has declined by 1,135.0%.
- Historical annual values: Fiscal year 2025: -$63.53 million | Fiscal year 2024: -$18.61 million | Fiscal year 2023: -$21.49 million | Fiscal year 2022: -$26.27 million | Fiscal year 2021: -$43.02 million | Fiscal year 2020: -$20.65 million | Fiscal year 2019: -$11.71 million | Fiscal year 2018: -$45.99 million | Fiscal year 2017: -$19.98 million | Fiscal year 2016: $33.57 million | Fiscal year 2015: -$46.99 million | Fiscal year 2014: -$36.41 million | Fiscal year 2013: -$43.88 million | Fiscal year 2012: -$21.43 million | Fiscal year 2011: -$16.52 million | Fiscal year 2010: -$11.18 million | Fiscal year 2009: -$5.14 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: